Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical, Inc. (NASDAQ: AMIX) is a forward-thinking medical device company focused on the development of innovative technologies for diagnosing and treating nervous system disorders. As a development-stage firm, Autonomix is pioneering a first-in-class technology platform that features a catheter-based microchip-enabled array. This array is capable of detecting and differentiating neural signals with an impressive sensitivity, as evidenced in animal studies.
The company's foremost project involves a catheter-based sensing and ablation technology intended to sense neural signals associated with pain or disease and precisely target those nerves for treatment. This technology aims to offer a better alternative to existing approaches, which often rely on systemic drugs like opioids that have limited effectiveness and troubling side effects, or invasive treatments that can miss target nerves and cause collateral damage.
Initially, Autonomix is focusing on treating pancreatic cancer-related pain. Traditional treatments such as opioids or ethanol injections offer limited relief and can result in severe side effects. The company is currently conducting a proof-of-concept (PoC) human clinical trial targeting the multi-billion-dollar pancreatic cancer market through transvascular RF ablation. This trial aims to mitigate pain in patients by ablating relevant somatic nerves using a transvascular approach, and patient enrollment is expected to be completed by year-end.
Recent achievements include the successful completion of the first three patient procedures in the PoC trial, the safe completion of an animal study demonstrating the efficacy of the technology in the renal artery, and the issuance of a U.S. patent covering the catheter-based technology for cancer-related pain. Additionally, the company has entered into a clinical site agreement with AKFA MEDLINE Ltd. and selected Clinical Accelerator and Qmed to manage trial operations and data.
Future milestones include launching a combined sensing and ablation clinical trial in 2025, submitting a de novo application in 2026, and seeking FDA clearance by 2027. Autonomix also has plans for its technology to address other conditions, including renal denervation and chronic pain management, making it a versatile platform with the potential to revolutionize how diseases involving the nervous system are treated.
For more information, visit autonomix.com and follow the company on social media platforms such as X, LinkedIn, Instagram, and Facebook.
Autonomix Medical, Inc. (NASDAQ: AMIX), a company focused on advancing precision nerve-targeted treatments, has been selected for a featured podium presentation at the 2024 Octane Medical Innovation Forum in Irvine, California on October 8-9, 2024. The forum brings together industry experts, entrepreneurs, investors, and thought leaders to discuss the latest insights and trends in the medical industry.
Brad Hauser, CEO of Autonomix, will present on the company's minimally invasive nerve-sensing, ablation, and verification platform technology. This first-in-class technology uses a catheter-based microchip sensing array antenna that can detect and differentiate neural signals with up to 3,000 times greater sensitivity than current technologies. The platform also includes proprietary radio frequency (RF) ablation technology for targeted nerve treatment, offering a precision-guided approach to addressing various conditions from chronic pain management to hypertension and cardiology.
Autonomix Medical (NASDAQ: AMIX) has announced promising 4-6 week preliminary results from its ongoing proof-of-concept human clinical trial for pancreatic cancer pain treatment. The trial, evaluating the safety and effectiveness of transvascular energy ablation of problematic nerves, showed significant pain reduction in responders:
- 60% of patients responded with a mean 83% reduction in pain (VAS scale: 8.0 to 1.33)
- 66% of responders reported a VAS pain score of 0 or 1
- 100% of responders experienced clinically meaningful pain relief
- Pain relief was observed as early as 1-day post-procedure
The company's proprietary technology uses a catheter-based microchip sensing array antenna to detect neural signals with high sensitivity, followed by precision-guided RF ablation. The trial is on track to complete enrollment by year-end 2024.
Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company focused on innovative technologies for diagnosing and treating nervous system diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 in New York, NY.
Key points:
- CEO Brad Hauser will present at the conference
- Management will be available for one-on-one meetings with qualified investors
- A video webcast of the presentation will be accessible on-demand from September 9, 2024, at 7:00 AM ET
- The webcast will be available on the Company's website for 90 days following the event
This presentation offers an opportunity for investors to gain insights into Autonomix's innovative medical technologies and future prospects.
Autonomix Medical, Inc. (NASDAQ: AMIX) announced that its technology and interim clinical trial findings will be featured in a podium presentation at the 2024 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress. The presentation, titled 'Rethinking pain management: transforming patient outcomes with precision mapping technology and celiac nerve RF ablation in end stage cancer', will be given by Dr. Askar Sabirov, the primary investigator for the company's ongoing proof-of-concept human clinical trial in pain associated with pancreatic cancer.
The presentation will take place on September 16th, 2024, as part of the 'Future AI Applications in Interventional Radiology' session. Autonomix CEO Brad Hauser emphasized the importance of engaging with the scientific community and aligning data release with their publication strategy to raise awareness for their innovative platform technology.
Autonomix Medical, Inc. (NASDAQ: AMIX) reported Q1 FY2025 financial results and provided a corporate update. Key highlights include:
1. Positive 7-day topline results from the first five lead-in patients in the ongoing proof-of-concept (PoC) human clinical trial for pancreatic cancer pain.
2. Appointment of Brad Hauser as President and CEO.
3. Licensing of FDA-cleared ablation technology from RF Innovations, Inc.
4. Net loss of $2.7 million for Q1 FY2025, compared to $0.9 million in the same period last year.
5. Cash position of $6.8 million as of June 30, 2024.
The company's technology platform uses a catheter-based microchip sensing array to detect neural signals and proprietary RF ablation to treat targeted nerves. Autonomix expects to report 4-6 week data from the PoC trial in Q3 CY2024 and complete enrollment in Q4 CY2024.
Autonomix Medical (NASDAQ: AMIX), a medical device company focusing on innovative technologies for nervous system diseases, has released a new CEO Corner segment. The segment, featuring CEO Brad Hauser, discusses the company's recent licensing agreement with RF Innovations for the intellectual property of the Apex 6 Radiofrequency Generator. This transaction marks a significant step in Autonomix's mission to revolutionize the diagnosis and treatment of nervous system disorders. The CEO Corner segment is now available on the company's website, providing investors and stakeholders with insights into this strategic move and its potential impact on Autonomix's future developments.
Autonomix Medical (NASDAQ: AMIX) has completed a licensing transaction with RF Innovations for the FDA-cleared Apex 6 Radiofrequency Generator. This transaction, involving 250,000 shares of common stock, grants Autonomix a perpetual non-exclusive worldwide and royalty-free license for the Apex 6 Generator intellectual property. The Apex 6 Generator will be a component of Autonomix's sensing and ablation system for FDA clearance.
The deal aligns with Autonomix's specifications for their ablation system and enhances their supply chain with RF Innovations' experienced manufacturing partner. Autonomix plans to utilize this technology in its strategic therapeutic areas, initially focusing on pancreatic cancer-related pain, with potential for follow-on indications.
Autonomix Medical (NASDAQ: AMIX), a medical device company focused on innovative technologies for diagnosing and treating nervous system diseases, has announced its participation in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024, at 4:00 PM ET. During this event, CEO Brad Hauser will provide a corporate overview and business outlook.
The event will feature a moderated discussion and allow investors to submit live questions. Autonomix will address as many questions as possible within the allotted time. A live video webcast will be available on the company's website, with a replay accessible for 90 days following the event.
Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company focused on innovative technologies for diagnosing and treating nervous system diseases, recently participated in a Virtual Investor 'What This Means' segment. CEO Brad Hauser discussed the company's recent definitive agreement with RF Innovations, Inc. to license the intellectual property for its Apex 6 Radiofrequency Generator.
The agreement is significant for Autonomix's development program, as it provides access to FDA-cleared ablation technology. This move aligns with the company's mission to revolutionize nervous system disease management. The segment, which offers insights into the implications of this licensing agreement, is now available for viewing online.
Autonomix Medical (NASDAQ: AMIX) has entered a definitive agreement with RF Innovations to license the intellectual property of the FDA-cleared Apex 6 Radiofrequency Generator. This ablation technology is designed to lesion neural tissue for pain management in the peripheral nervous system. The transaction, valued at 250,000 shares of common stock, grants Autonomix a perpetual non-exclusive worldwide and royalty-free license. Autonomix plans to utilize this technology in its strategic therapeutic areas, potentially simplifying its regulatory strategy. The company is initially developing its technology to address pancreatic cancer-related pain, with plans for follow-on indications. This agreement is expected to accelerate Autonomix's journey in revolutionizing the diagnosis and treatment of diseases involving the nervous system.
FAQ
What is the current stock price of Autonomix Medical (AMIX)?
What is the market cap of Autonomix Medical (AMIX)?
What is Autonomix Medical, Inc. focusing on?
What is the primary technology of Autonomix?
What is the initial application of Autonomix's technology?
What are some recent achievements of Autonomix Medical, Inc.?
Who are Autonomix’s clinical partners?
What are the future milestones for Autonomix?
What other conditions might Autonomix's technology address?
How does Autonomix's technology differ from current treatments?
What is the significance of the PoC human clinical trial?
Where can I find more information about Autonomix Medical, Inc.?
